Humanized anti-IFN-γ (HuZAF) in the treatment of psoriasis.

[1]  Y. Wasfi,et al.  Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. , 2014, The Journal of allergy and clinical immunology.

[2]  J. Krueger,et al.  Putting together the psoriasis puzzle: an update on developing targeted therapies , 2012, Disease Models & Mechanisms.

[3]  M. Suárez-Fariñas,et al.  Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. , 2010, The Journal of investigative dermatology.

[4]  Mayte Suárez-Fariñas,et al.  Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. , 2009, The Journal of allergy and clinical immunology.

[5]  D. Hommes,et al.  Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn’s disease , 2006, Gut.

[6]  A. Bowcock,et al.  Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. , 2004, Trends in immunology.

[7]  N. F. Landolfi,et al.  A potent neutralizing monoclonal antibody can discriminate amongst IFNgamma from various primates with greater specificity than can the human IFNgamma receptor complex. , 1999, Molecular immunology.

[8]  G. Chodorowska.  Plasma concentrations of IFN‐γ and TNF‐α: in psoriatic patients before and after local treatment with dithranol ointment , 1998 .

[9]  A. Gottlieb,et al.  PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy , 1994, The Journal of experimental medicine.

[10]  M. Yamamura,et al.  The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response. , 1993, The Journal of investigative dermatology.